Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 08 December 2016 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Thursday released final guidance on the implementation of the Drug Supply Chain Security Act (DSCSA), though it’s also seeking comment on a new section describing when manufacturers should notify FDA of a high risk that a product is illegitimate.
Under the new section, which FDA says is being distributed “for comment purposes only,” the agency offers its interpretation of Section 582(b)(4)(B)(ii)(II) of the Food, Drugs and Cosmetics Act (FD&C Act), which requires manufacturers to make notifications in certain circumstances for products that pose a high risk of illegitimacy.
“FDA interprets this provision to require manufacturers to notify (1) FDA and (2) the manufacturer’s immediate trading partners (that the manufacturer has reason to believe may have in the trading partner’s possession a product manufactured by, or purported to be a product manufactured by, the manufacturer) in three general scenarios:
The new section, entitled “For Manufacturers: High Risk of Illegitimacy Notifications,” also offers examples of scenarios involving high risks of illegitimacy in which a manufacturer should make a notification.
In addition to the added section, FDA says it made minor changes to the Form FDA 3911 and to the instructions for completing the form.
The finalized portions of the guidance, first drafted in June 2014, aim to help companies remove illegitimate medicines from the US market promptly by notifying FDA and trading partners after the manufacturers determine or are notified by FDA or a trading partner that there is a high risk that a product is illegitimate.
And beginning next November, pharmaceutical companies will be required to mark their products with a National Drug Code (NDC), serial number, lot number and expiration date in both machine-readable and human-readable formats.
Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry
Tags: DSCSA, track and trace, supply chain pharmaceuticals, FDA guidance